US2013217726A1PendingUtilityA1

Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof

44
Assignee: HOWARD FLOREY INSTPriority: Nov 19, 2007Filed: Feb 6, 2013Published: Aug 22, 2013
Est. expiryNov 19, 2027(~1.4 yrs left)· nominal 20-yr term from priority
A61P 25/00A61P 25/28C07D 405/04
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions.

Claims

exact text as granted — not AI-modified
1 - 11 . (canceled) 
     
     
         12 . A method for enhancing memory, learning or combinations thereof in a subject, the method comprising administering to the subject a compound of Formula (I): 
       
         
           
           
               
               
           
         
       
       wherein
 A is aryl, heteroaryl carbocyclyl or heterocyclyl, each of which may be optionally substituted, when R 1  is NHCOR 8 ; or
 quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridyl, phthalazinyl or pteridinyl, each of which may be optionally substituted, when R 1  is NR 7 R 8 , NHCOR 8 , N(COR 8 ) 2 , N(COR 7 )(COR 8 ), N═CHOR 8  or N═CHR 8 ; 
 
 X is O, NR′ or S, wherein R′ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted acyl, optionally substituted heteroaryl, optionally substituted carbocyclyl or optionally substituted heterocyclyl; 
 R 7  and R 8  are independently selected from hydrogen, optionally substituted alkyl, optionally substituted aryl, or R 7  and R 8 , together with the nitrogen atom to which they are attached form a 3-8-membered ring which may be optionally substituted; 
 R 2  is CN, CO 2 R 9 , C(O)O(O)R 9 , C(O)R 9  or C(O)NR 9 R 10  wherein R 9  and R 10  are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, each of which may be optionally substituted, and hydrogen; or R 9  and R 10 , together with the nitrogen atom to which they are attached, form a 3-8-membered ring which may be optionally substituted; 
 R 3 -R 6  are independently selected from hydrogen, halo, nitro, cyano alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, carbocyclyl, hydroxy, alkoxy, alkenyloxy, alkynyloxy, alkynyloxy, aryloxy, heteroaryloxy, heterocyclyloxy, amino, acyl, acyloxy, carboxy, carboxyester, methylenedioxy, amido, thio, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, heterocyclylthio, carbocyclylthio, acylthio and azido, each of which may be optionally substituted where appropriate, or any two adjacent R 3 -R 6 , together with the atoms to which they are attached, form a 3-8-membered ring which may be optionally substituted; and 
 Y is hydrogen or C 1-10 alkyl, 
 
       or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         13 . The method of  claim 12 , where R 1  is NHCOR 8 . 
     
     
         14 . The method of  claim 12 , wherein R 1  is NHCOC 1-6 alkyl, NHCOphenyl or NHCObenzyl. 
     
     
         15 . The method of  claim 12 , wherein A is selected from quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridyl, phthalazinyl and pteridinyl, each of which may be substituted or unsubstituted. 
     
     
         16 . The method of  claim 12 , wherein R 1  is NHCOC 1-6 alkyl and A is selected from quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridyl, phthalazinyl and pteridinyl, each of which may be substituted or unsubstituted. 
     
     
         17 . The method of  claim 12 , wherein the compound is selected from:
 Ethyl 2-amino-7-hydroxy-4-quinolin-4-yl-4H-chromene-3-carboxylate,   Ethyl 2-(acetylamino)-7-hydroxy-4-pyridin-3-yl-4H-chromene-3-carboxylate,   Ethyl 2-amino-7-hydroxy-4-quinolin-3-yl-4H-chromene-3-carboxylate and   Ethyl 2-(acetylamino)-7-hydroxy-4-quinolin-3-yl-4H-chromene-3-carboxylate   and pharmaceutically acceptable salts and solvates thereof.   
     
     
         18 . The method of  claim 12 , wherein R 2  is CO 2 R 9  and R 3 -R 6  are selected from hydrogen, acyl, acyloxy, carboxy and carboxyester.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.